Alecensa
Roche’s Alecensa topples Pfizer’s Xalkori in Asian patients with ALK+ advanced lung cancer
October 23, 2018Manufacturing and Production, Research and Development Alecensa, Cancer, ESMO 2018, Roche, lung cancer, pharma
Following up on the reveal of data concerning its immunotherapy Tecentriq in combination with chemotherapy in the treatment of non-small …
Roche’s Alecensa secures NICE approval in NSCLC after topping Pfizer’s Xalkori
June 28, 2018Sales and Marketing Alecensa, NICE, NSCLC, Pfizer, Xalkori, pharma
UK health watchdog NICE has given its approval for Roche’s selective ALK inhibitor Alecensa (alectinib) for use on the NHS, …
Roche’s lung cancer drug beats Pfizer rival in study
April 10, 2017Research and Development, Sales and Marketing Alecensa, Roche
Roche has announced that its drug Alecensa (alectinib) succeeded in meeting its primary endpoint in a Phase 3 trial assessing …
Roche granted further good news by FDA
October 11, 2016Manufacturing and Production Actembra, Alecensa, FDA, Lucentis, Roche, United States, america
Roche was given further good news by FDA after receiving a Priority Review for its Lucentis drug – this news …
Roche’s Alecensa receives second FDA Breakthrough Therapy Designation
October 4, 2016Manufacturing and Production ALK+, Alecensa, FDA, Roche, alk, crizotinib
Alecensa has been designated as a breakthrough therapy, which will speed up the process towards FDA approval, should clinical trials …
Roche lung cancer drug Alecensa gets rapid US approval
December 14, 2015Sales and Marketing Alecensa, FDA, Genentech, Roche, accelerated approval, alectinib, lung cancer, non-small cell lung cancer
The US health watchdog has approved Alecensa, a drug for people with certain types of non-small cell lung cancer manufactured …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
